- Home
- PSTL vs NKTX Comparison
PSTL vs NKTX Comparison
Compare PSTL & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- NKTX
- Stock Information
- Founded
- PSTL 2018
- NKTX 2015
- Country
- PSTL United States
- NKTX United States
- Employees
- PSTL N/A
- NKTX N/A
- Industry
- PSTL Real Estate Investment Trusts
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- NKTX Health Care
- Exchange
- PSTL Nasdaq
- NKTX Nasdaq
- Market Cap
- PSTL 320.0M
- NKTX 363.4M
- IPO Year
- PSTL 2019
- NKTX 2020
- Fundamental
- Price
- PSTL $14.33
- NKTX $3.92
- Analyst Decision
- PSTL Buy
- NKTX Strong Buy
- Analyst Count
- PSTL 2
- NKTX 6
- Target Price
- PSTL $15.75
- NKTX $17.33
- AVG Volume (30 Days)
- PSTL 79.3K
- NKTX 531.4K
- Earning Date
- PSTL 10-28-2024
- NKTX 11-07-2024
- Dividend Yield
- PSTL 6.67%
- NKTX N/A
- EPS Growth
- PSTL N/A
- NKTX N/A
- EPS
- PSTL 0.09
- NKTX N/A
- Revenue
- PSTL $68,445,000.00
- NKTX N/A
- Revenue This Year
- PSTL N/A
- NKTX N/A
- Revenue Next Year
- PSTL $12.21
- NKTX N/A
- P/E Ratio
- PSTL $165.15
- NKTX N/A
- Revenue Growth
- PSTL 15.46
- NKTX N/A
- 52 Week Low
- PSTL $12.98
- NKTX $1.31
- 52 Week High
- PSTL $15.15
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- PSTL 41.96
- NKTX 28.36
- Support Level
- PSTL $14.50
- NKTX $3.83
- Resistance Level
- PSTL $14.68
- NKTX $4.28
- Average True Range (ATR)
- PSTL 0.19
- NKTX 0.33
- MACD
- PSTL -0.05
- NKTX -0.12
- Stochastic Oscillator
- PSTL 8.82
- NKTX 4.50
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.